Korro Bio FY2026 Earnings Forecast Raised by HC Wainwright

Korro Bio, Inc. (NASDAQ:KRRO) – Equities research analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of Korro Bio in a research note issued to investors on Friday, November 6th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($4.26) for the year, up from their prior estimate of ($4.88). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($4.92) per share. HC Wainwright also issued estimates for Korro Bio’s Q4 2026 earnings at ($0.73) EPS, Q3 2027 earnings at ($1.25) EPS and FY2027 earnings at ($5.03) EPS.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.16.

KRRO has been the topic of several other reports. Jefferies Financial Group set a $15.00 target price on shares of Korro Bio in a research report on Tuesday, October 6th. Wall Street Zen raised shares of Korro Bio from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Korro Bio in a research note on Friday, October 2nd. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Korro Bio has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Korro Bio Price Performance

Shares of KRRO stock opened at $14.96 on Tuesday. The firm has a market cap of $220.36 million, a P/E ratio of -1.65 and a beta of 3.23. Korro Bio has a 1-year low of $5.20 and a 1-year high of $36.79. The firm’s 50-day simple moving average is $11.66 and its 200-day simple moving average is $12.08.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Korro Bio during the second quarter worth approximately $10,776,000. Affinity Asset Advisors LLC acquired a new stake in shares of Korro Bio in the first quarter worth $8,002,000. Nantahala Capital Management LLC purchased a new position in shares of Korro Bio in the 2nd quarter valued at $8,699,274. ADAR1 Capital Management LLC purchased a new position in shares of Korro Bio in the 2nd quarter valued at $7,118,000. Finally, Renaissance Technologies LLC raised its stake in shares of Korro Bio by 81.9% in the 1st quarter. Renaissance Technologies LLC now owns 136,227 shares of the company’s stock valued at $1,542,000 after acquiring an additional 61,327 shares during the period. 13.18% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Korro Bio

In other Korro Bio news, Director Jean Formela sold 28,468 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $14.00, for a total transaction of $398,552.00. Following the completion of the sale, the director directly owned 141,053 shares in the company, valued at $1,974,742. This represents a 16.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Lynx1 Capital Management Lp acquired 25,124 shares of the business’s stock in a transaction dated Monday, October 26th. The stock was purchased at an average price of $11.75 per share, for a total transaction of $295,207.00. Following the completion of the acquisition, the insider owned 1,624,789 shares in the company, valued at approximately $19,091,270.75. This trade represents a 1.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 79,809 shares of company stock valued at $884,919 and sold 36,126 shares valued at $502,148. 4.80% of the stock is owned by company insiders.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company developing RNA editing medicines for genetically driven diseases. The company’s approach is designed to make targeted changes to messenger RNA, potentially correcting or altering disease-related genetic instructions without permanently changing a patient’s DNA.

Korro Bio’s technology platform uses programmable oligonucleotides to guide RNA editing in specific cells and tissues. Its lead development program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene that can lead to liver and lung disease.